Bladder Cancer

January 2012

Best Article! Immunocytology Is a Strong Predictor of Bladder Cancer Presence in Patients With Painless Hematuria: A Multicentre Study
Cha, EK, Tirsar, L, Schwentner, C.

November 2011

Lymph Node Dissection Technique Is More Important Than Lymph Node Count in Identifying Nodal Metastases in Radical Cystectomy Patients: A Comparative Mapping Study
Dorin, R, Daneshmand, S, Eisenberg, M.

Standard or Extended Lymphadenectomy in Radical Cystectomy: What Metric of Surgical Quality for Lymph Node Dissections Matters in Improving Patient Outcomes?
Kim, S, Karnes, J.

October 2011

Prevention of Bladder Tumours after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: A Prospective, Multicentre, Randomised Clinical Trial of a Single Postoperative Intravesical Dose of Mitomycin C (the ODMIT-C Trial)
O’Brien, T. Ray, E, Singh, R.

Postoperative Intravesical Therapy to Prevent Bladder Tumor Recurrence: Are We Ready to Listen Yet?
Boorjian, S.

Smoking Status Is a Risk Factor for Recurrence After Transurethral Resection of Non–Muscle-Invasive Bladder Cancer
Lammers, R, Witjes, W, Hendricksen, K.

Identifying Risk Factors in Patients With Non–Muscle-Invasive Bladder Cancer: Clinical Implications
Schmitz-Dräger, B.J.

September 2011
The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables
Fernandez-Gomez, J, Madero, R, Solsona, E.

How Well Can You Actually Predict Which Non–Muscle-Invasive Bladder Cancer Patients Will Progress?
Sylvester, R.J.

Reply from Authors re: Richard J. Sylvester. How Well Can You Actually Predict Which Non–Muscle-Invasive Bladder Cancer Patients Will Progress? Eur Urol 2011;60:431–3fileadmin/count.php?f=fileadmin/European_Urology/Platinum_Priority/2011/September_2011/Jesus_Fernandez-Gomez_REPLY.pdf
Fernandez-Gomez, J.

2011- August

Best Article! Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population
Neuzillet, Y, Tillou, X, Mathieu, R.

Platinum Priority!Long-term Follow-up of Bladder Cancer Patients with Disseminated Tumour Cells in Bone Marrow
Retz, M,  Rotering, J, Nawroth, R.

Platinum Priority!Detection of Tumor Cells in the Bone Offers Independent Prognostic Value in Bladder Cancer Patients: The Clinical and Basic Science Perspective
DeGraff,  D, Clark, P.

2011 - July
Platinum Priority!Bacillus Calmette-Guérin Without Maintenance Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer
Herr, HW,  Dal bagni, G, Donat, SM.

Platinum Priority!Thirty-Five Years of Intravesical Bacillus Calmette-Guérin for Bladder Cancer: Where Now?
Catto, J.

2011- May
Best Article! High Expression of Karyopherin-?2 Defines Poor Prognosis in Non–Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy 
Jensen, J, Munksgaard, P, Sørensen, C.

Platinum Priority!Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node–Positive Urothelial Bladder Cancer Following Radical Cystectomy
May, M, Herrmann, E, Bolenz, C.
With the following accompanying editorial
Improving the Outcome for Invasive Bladder Cancer: The Debate Regarding Pelvic Lymphadenectomy Moves From If to How 
Catto, J.

2011 -  April
Platinum Priority! Irrigation of Continent Catheterizable Ileal Pouches: Tap Water Can Replace Sterile Solutions Because It Is Safe, Easy, and Economical
Birkhäuser, F,D, Zehnder, P,  Roth, B.
With the following accompanying editorial
The Quest for a Better Bladder From Bowel
Chin, J.

2011- March
Best Article!NRAMP1 and hGPX1 Gene Polymorphism and Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer
Chiong, E, Kesavan, A, Mahendran, R.

Best Article!Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)
Oosterlinck, W, Kirkali, Z, Sylvester, R.
With the following accompanying editorial
Should All Patients Receive an Immediate Chemotherapeutic Drug Instillation After Resection of Papillary Bladder Tumors? 
Oosterlinck, W, Sylvester, R, Babjuk, M.

2011 - February
Best Article!Diagnostic, Staging, and Grading of Urothelial Carcinomas from Urine: Performance of BCA-1, a Mini-Array Comparative Genomic Hybridisation–Based Test
Larré, S, Camparo, P, Comperat, E.

Platinum Priority!Readaptation of the Peritoneum Following Extended Pelvic Lymphadenectomy and Cystectomy Has a Significant Beneficial Impact on Early Postoperative Recovery and Complications: Results of a Prospective Randomized Trial
Roth,B, Birkhäuser, F, D, Zehnder, P.
With the following accompanying editorial
For Wider Acceptance of Radical Cystectomy and Extended Pelvic Lymphadenectomy
Maffezzini, M.

Platinum Priority!Defining Morbidity of Robot-Assisted Radical Cystectomy Using a Standardized Reporting Methodology
Hayn, M,H, Hellenthal, N, J, Hussain, A.
With the following accompanying editorial
Is Robot-Assisted Radical Cystectomy the Right Way to Reduce Complications in Patients Undergoing Radical Cystectomy? 
Novara, N, Ficarra, V, Zattoni, F.

2011 - January
Best Article! Raman Molecular Imaging: A Novel Spectroscopic Technique for Diagnosis of Bladder Cancer in Urine Specimens 
Shapiro, A, Gofrit, O, Pizov, G.

Best Article! Stress Proteins and Cytokines are Urinary Biomarkers for Diagnosis and Staging of Bladder Cancer 
Margel, D, Pesvner-Fischer, M, Baniel, J.

2010 - October
Do Patients Benefit from Routine Follow-up to Detect Recurrences After Radical Cystectomy and Ileal Orthotopic Bladder Substitution?  
Giannarini, G, Kessler, TK, Thoeny, H,C.

With the following accompanying editorial
Invasive Bladder Cancer and the Role of Follow-up: Should We Consider the Match Over at Radical Cystectomy or Should We Play for Extra Time?  
Colombo, R.

2010 -  September
Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer
Zuiverloon, T, Lockwood, G.

2010 - August
Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial
Divrik, RT.

Second Resection for Non-Muscle-Invasive Bladder Carcinoma: Current Role and Future Perspectives  
Babjuk, M.

With the following accompanying editorial
Does Routine Second Transurethral Resection Affect the Long-Term Outcome of Patients with T1 Bladder Cancer? Why a Flawed Randomized Controlled Trial Cannot Address the Issue 
Novara, G. Ficarra, V.

With the following reply to the editorial
Reply from Authors re: Marko Babjuk. Second Resection for Non-Muscle-Invasive Bladder Carcinoma: Current Role and Future Perspectives. Eur Urol 2010;58:191–2 and Giacomo Novara, Vincenzo Ficarra. Does Routine Second Transurethral Resection Affect the Long-Term Outcome of Patients with T1 Bladder Cancer? Why a Flawed Randomized Controlled Trial Cannot Address the Issue. Eur Urol 2010;58:193–4  
Divrik, RT. Sahin, AF.

With the following accompanying editorial
The Learning Curve of Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium
Studer, E.

With the following reply to the editorial
Reply from Authors re: Urs E. Studer, Laurence Collette. Robot-Assisted Cystectomy: Does It Meet Expectations? Eur Urol 2010;58:203–4  
Hayn, MH. Hussain, A.

2010 - May
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder 
Sylvester, R, Brausi, M.

With the following accompanying editorial
New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma  
Babjuk, M.

With the following reply to the editorial
Reply from Authors re: Marko Babjuk. New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma. Eur Urol 2010;57:774–6  
Sylvester, R, Brausi, M.

2010 - February
Prospective Randomized Controlled Trial of Robotic versus Open Radical Cystectomy for Bladder Cancer: Perioperative and Pathologic Results 
Nix, J, Smith, A.

With the following accompanying editorial
Moving Towards Evidence-based Surgery  
Hakenberg, O.

With the following reply to the editorial
Reply from Authors re: Oliver W. Hakenberg. Moving Towards Evidence-based Surgery. Eur Urol 2010;57:202–3  
Nix, J.

A New Multimodality Technique Accurately Maps the Primary Lymphatic Landing Sites of the Bladder 
Roth, B.

With the following reply to the editorial
Extent of Pelvic Lymph Node Dissection During Radical Cystectomy: Where and Why!  
Herr, H.


2010 -  January
Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles 
Birkhahn, M, Williams A, J.

With the following accompanying editorial
In Search of the Perfect Crystal Ball for Ta Urothelial Cancer  
Chin, J.

With the following reply to the editorial
Reply from Authors re: Joseph L. Chin. In Search of the Perfect Crystal Ball for Ta Urothelial Cancer. Eur Urol 2010;57:21–2  
Birkhahn, M.

Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-?2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study  
Malmström, P, Johansson, R.

With the following accompanying editorial
What is the Optimal Treatment Strategy for T1 Bladder Tumors?  
Babjuk, M.